In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Joseph Haas

Joseph Haas is a senior writer for Informa’s pharmaceutical news publications, with more than eight years covering the biopharmaceutical industry. He previously worked in public affairs for a real estate trade association and wrote about housing and real estate before moving into healthcare. Most recently, he was managing editor of a newsletter publisher, leading its coverage of the implementation of the Medicare Part D prescription drug benefit. Joe’s areas of expertise include business development, mergers and acquisitions, infectious diseases and liver diseases, including hepatitis C, hepatitis B and non-alcoholic steatohepatitis (NASH). He edits the popular Deal Watch column and enjoys profiling start-up companies. 

Latest From Joseph Haas

Sarepta’s Exondys 51 Successor On Clinical Hold, But Quick Resolution Expected

The FDA placed a hold on the Phase II study of SRP-5051, which uses the company’s next-generation peptide conjugation technology, but Sarepta thinks it can address safety questions in short order.

Drug Safety Clinical Trials

Asia Deal Watch: invoX Builds Novel Pipeline Through $161m F-star Acquisition

F-star's novel bispecific technology attracts Sino Biopharma-affiliated acquisition, Shionogi agreement with GARDP brings antibiotic cefiderocol to 135 countries, deal with WinHealth covering Greater China expands Quoin’s licensing of Netherton syndrome candidate to 60 nations, Kyorin and CellGenTech team up in Fabry disease.

Deal Watch Business Strategies

Are Market Conditions Setting Up A Biopharma M&A Wave?

A new EY report contends that declining biotech valuations and the need for large pharma to add pipeline assets may create conditions for a buyer’s market – although year-to-date M&A activity has been lackluster.

M & A Business Strategies

Athira Says Phase II Alzheimer’s Miss Will Inform Ongoing Phase III Study

Athira hoped a small Phase II study would show a benefit on working memory processing speed, but it missed its primary and all secondary endpoints, reducing confidence in the Phase III program.

Clinical Trials Business Strategies

Clovis Withdraws Rubraca Ovarian Cancer Indication Due To Survival Imbalance

Third-line BRCA-mutated ovarian cancer indication is not a major loss for Rubraca, but Clovis also faces delay in filing to add first-line ovarian cancer therapy to product label.

Clinical Trials Drug Safety

Third Rock Thinks Its Model Reassures Investors In Difficult Times

New fund will include some later-stage investments in portfolio companies, in recognition of the currently tough environment for privately held biotechs.

Financing Business Strategies
See All
UsernamePublicRestriction

Register